Half-year report · HY
4886.TEDINET S100WZ8Y
Period2025-04-01 → 2025-09-30
Filed2025-11-07
StandardJapan GAAP
ConsolidatedYes
Data checks14 of 14 passed
Key figures · 44
| Metric | Value | Period | Scope | Source row |
|---|---|---|---|---|
| Revenue | ¥35.3bn | 2025-04-01 → 2025-09-30 | Cons. | Net sales |
| Revenue | ¥64.1bn | 2024-04-01 → 2025-03-31 | Cons. | Net sales (5-year summary) |
| Revenue | ¥32.4bn | 2024-04-01 → 2024-09-30 | Cons. | Net sales |
| Operating income | ¥2.6bn | 2025-04-01 → 2025-09-30 | Cons. | Operating income |
| Operating income | ¥3.3bn | 2024-04-01 → 2024-09-30 | Cons. | Operating income |
| Ordinary income | ¥2.7bn | 2025-04-01 → 2025-09-30 | Cons. | Ordinary income |
| Ordinary income | ¥5.1bn | 2024-04-01 → 2025-03-31 | Cons. | Ordinary income loss (5-year summary) |
| Ordinary income | ¥3.3bn | 2024-04-01 → 2024-09-30 | Cons. | Ordinary income |
| Profit before tax | ¥2.8bn | 2025-04-01 → 2025-09-30 | Cons. | Income before income taxes |
| Profit before tax | ¥3.3bn | 2024-04-01 → 2024-09-30 | Cons. | Income before income taxes |
| Net income (owners) | ¥2.2bn | 2025-04-01 → 2025-09-30 | Cons. | Profit loss attributable to owners of parent |
| Net income (owners) | ¥5.1bn | 2024-04-01 → 2025-03-31 | Cons. | Profit loss attributable to owners of parent (5-year summary) |
| Net income (owners) | ¥2.6bn | 2024-04-01 → 2024-09-30 | Cons. | Profit loss attributable to owners of parent |
| Net income | ¥2.4bn | 2025-04-01 → 2025-09-30 | Cons. | Profit loss |
| Net income | ¥2.6bn | 2024-04-01 → 2024-09-30 | Cons. | Profit loss |
| Total assets | ¥108.8bn | at 2025-09-30 | Cons. | Assets |
| Total assets | ¥103.9bn | at 2025-03-31 | Cons. | Assets |
| Total assets | ¥88.3bn | at 2024-09-30 | Cons. | Total assets (5-year summary) |
| Total liabilities | ¥36.2bn | at 2025-09-30 | Cons. | Liabilities |
| Total liabilities | ¥32.3bn | at 2025-03-31 | Cons. | Liabilities |
| Net assets / equity | ¥72.6bn | at 2025-09-30 | Cons. | Net assets |
| Net assets / equity | ¥71.6bn | at 2025-03-31 | Cons. | Net assets |
| Net assets / equity | ¥64.2bn | at 2024-09-30 | Cons. | Net assets (5-year summary) |
| Cash and deposits | ¥6.6bn | at 2025-09-30 | Cons. | Cash and deposits |
| Cash and deposits | ¥10.6bn | at 2025-03-31 | Cons. | Cash and deposits |
| Cash & equivalents | ¥7.1bn | at 2025-09-30 | Cons. | Cash and cash equivalents |
| Cash & equivalents | ¥10.6bn | at 2025-03-31 | Cons. | Cash and cash equivalents |
| Cash & equivalents | ¥13.7bn | at 2024-09-30 | Cons. | Cash and cash equivalents |
| Cash & equivalents | ¥16.7bn | at 2024-03-31v | Cons. | Cash and cash equivalents |
| Operating cash flow | ¥1.1bn | 2025-04-01 → 2025-09-30 | Cons. | Net cash provided by used in operating activities |
| Operating cash flow | ¥2.5bn | 2024-04-01 → 2025-03-31 | Cons. | Net cash provided by used in operating activities (5-year summary) |
| Operating cash flow | ¥1.2bn | 2024-04-01 → 2024-09-30 | Cons. | Net cash provided by used in operating activities |
| Investing cash flow | −¥6.0bn | 2025-04-01 → 2025-09-30 | Cons. | Net cash provided by used in investment activities |
| Investing cash flow | −¥6.1bn | 2024-04-01 → 2025-03-31 | Cons. | Net cash provided by used in investing activities (5-year summary) |
| Investing cash flow | −¥1.8bn | 2024-04-01 → 2024-09-30 | Cons. | Net cash provided by used in investment activities |
| Financing cash flow | ¥1.4bn | 2025-04-01 → 2025-09-30 | Cons. | Net cash provided by used in financing activities |
| Financing cash flow | −¥3.0bn | 2024-04-01 → 2025-03-31 | Cons. | Net cash provided by used in financing activities (5-year summary) |
| Financing cash flow | −¥2.4bn | 2024-04-01 → 2024-09-30 | Cons. | Net cash provided by used in financing activities |
| EPS (basic) | ¥78.49 | 2025-04-01 → 2025-09-30 | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥179.95 | 2024-04-01 → 2025-03-31 | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥90.36 | 2024-04-01 → 2024-09-30 | Cons. | Basic earnings loss per share (5-year summary) |
| Equity ratio | 61.5% | at 2025-09-30 | Cons. | Equity to asset ratio (5-year summary) |
| Equity ratio | 62.9% | at 2025-03-31 | Cons. | Equity to asset ratio (5-year summary) |
| Equity ratio | 72.7% | at 2024-09-30 | Cons. | Equity to asset ratio (5-year summary) |
Periods use the dates stated in the filing. d = earlier-year period dated by calendar; v = that date confirmed by the company's own earlier filing.
Segments · 37
| Segment | Item | Period | Value |
|---|---|---|---|
| Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segments | revenue | 2025-04-01 → 2025-09-30 | ¥141m |
| Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segments | revenue external | 2025-04-01 → 2025-09-30 | ¥99m |
| Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segments | revenue intersegment | 2025-04-01 → 2025-09-30 | ¥42m |
| Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segments | segment profit | 2025-04-01 → 2025-09-30 | −¥15m |
| Reconciling Itemsreconciling | revenue | 2025-04-01 → 2025-09-30 | −¥42m |
| Reconciling Itemsreconciling | revenue intersegment | 2025-04-01 → 2025-09-30 | −¥42m |
| Reconciling Itemsreconciling | segment profit | 2025-04-01 → 2025-09-30 | −¥870m |
| Animal Health Businessreportable segment | revenue | 2025-04-01 → 2025-09-30 | ¥3.8bn |
| Animal Health Businessreportable segment | revenue external | 2025-04-01 → 2025-09-30 | ¥3.8bn |
| Animal Health Businessreportable segment | segment profit | 2025-04-01 → 2025-09-30 | ¥282m |
| Oversea Businessreportable segment | revenue | 2025-04-01 → 2025-09-30 | ¥2.1bn |
| Oversea Businessreportable segment | revenue external | 2025-04-01 → 2025-09-30 | ¥2.1bn |
| Oversea Businessreportable segment | segment profit | 2025-04-01 → 2025-09-30 | ¥132m |
| Pharmaceutical Businessreportable segment | revenue | 2025-04-01 → 2025-09-30 | ¥29.3bn |
| Pharmaceutical Businessreportable segment | revenue external | 2025-04-01 → 2025-09-30 | ¥29.3bn |
| Pharmaceutical Businessreportable segment | segment profit | 2025-04-01 → 2025-09-30 | ¥3.1bn |
| Total Of Reportable Segments And Otherssegment total | revenue | 2025-04-01 → 2025-09-30 | ¥35.3bn |
| Total Of Reportable Segments And Otherssegment total | revenue external | 2025-04-01 → 2025-09-30 | ¥35.3bn |
| Total Of Reportable Segments And Otherssegment total | revenue intersegment | 2025-04-01 → 2025-09-30 | ¥42m |
| Total Of Reportable Segments And Otherssegment total | segment profit | 2025-04-01 → 2025-09-30 | ¥3.5bn |
| Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segments | revenue | 2024-04-01 → 2024-09-30 | ¥151m |
| Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segments | revenue external | 2024-04-01 → 2024-09-30 | ¥113m |
| Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segments | revenue intersegment | 2024-04-01 → 2024-09-30 | ¥38m |
| Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segments | segment profit | 2024-04-01 → 2024-09-30 | −¥4m |
| Reconciling Itemsreconciling | revenue | 2024-04-01 → 2024-09-30 | −¥38m |
| Reconciling Itemsreconciling | revenue intersegment | 2024-04-01 → 2024-09-30 | −¥38m |
| Reconciling Itemsreconciling | segment profit | 2024-04-01 → 2024-09-30 | −¥652m |
| Animal Health Businessreportable segment | revenue | 2024-04-01 → 2024-09-30 | ¥3.6bn |
| Animal Health Businessreportable segment | revenue external | 2024-04-01 → 2024-09-30 | ¥3.6bn |
| Animal Health Businessreportable segment | segment profit | 2024-04-01 → 2024-09-30 | ¥177m |
| Pharmaceutical Businessreportable segment | revenue | 2024-04-01 → 2024-09-30 | ¥28.6bn |
| Pharmaceutical Businessreportable segment | revenue external | 2024-04-01 → 2024-09-30 | ¥28.6bn |
| Pharmaceutical Businessreportable segment | segment profit | 2024-04-01 → 2024-09-30 | ¥3.8bn |
| Total Of Reportable Segments And Otherssegment total | revenue | 2024-04-01 → 2024-09-30 | ¥32.4bn |
| Total Of Reportable Segments And Otherssegment total | revenue external | 2024-04-01 → 2024-09-30 | ¥32.4bn |
| Total Of Reportable Segments And Otherssegment total | revenue intersegment | 2024-04-01 → 2024-09-30 | ¥38m |
| Total Of Reportable Segments And Otherssegment total | segment profit | 2024-04-01 → 2024-09-30 | ¥4.0bn |
Segment names come from EDINET member IDs; not yet mapped to a common taxonomy.
All source rows · 488
| Item | Context | Value | Unit |
|---|---|---|---|
| Liabilities | InterimInstant | 36178000000 | JPY |
| Capital stock | Prior1YearInstant | 1197000000 | JPY |
| Capital stock | InterimInstant | 1197000000 | JPY |
| Capital surplus | Prior1YearInstant | － | JPY |
| Capital surplus | InterimInstant | 31000000 | JPY |
| Retained earnings | Prior1YearInstant | 59545000000 | JPY |
| Retained earnings | InterimInstant | 60921000000 | JPY |
| Treasury stock | Prior1YearInstant | -704000000 | JPY |
| Treasury stock | InterimInstant | -658000000 | JPY |
| Shareholders equity | Prior1YearInstant | 60039000000 | JPY |
| Shareholders equity | InterimInstant | 61492000000 | JPY |
| Valuation difference on available for sale securities | Prior1YearInstant | 4853000000 | JPY |
| Valuation difference on available for sale securities | InterimInstant | 5695000000 | JPY |
| Foreign currency translation adjustment | Prior1YearInstant | － | JPY |
| Foreign currency translation adjustment | InterimInstant | -721000000 | JPY |
| Remeasurements of defined benefit plans | Prior1YearInstant | 417000000 | JPY |
| Remeasurements of defined benefit plans | InterimInstant | 389000000 | JPY |
| Valuation and translation adjustments | Prior1YearInstant | 5271000000 | JPY |
| Valuation and translation adjustments | InterimInstant | 5364000000 | JPY |
| Non controlling interests | Prior1YearInstant | 6245000000 | JPY |
| Non controlling interests | InterimInstant | 5737000000 | JPY |
| Net assets | Prior1YearInstant | 71555000000 | JPY |
| Net assets | InterimInstant | 72594000000 | JPY |
| Liabilities and net assets | Prior1YearInstant | 103889000000 | JPY |
| Liabilities and net assets | InterimInstant | 108773000000 | JPY |
| Net sales | Prior1InterimDuration | 32371000000 | JPY |
| Net sales | InterimDuration | 35253000000 | JPY |
| Cost of sales | Prior1InterimDuration | 16463000000 | JPY |
| Cost of sales | InterimDuration | 18267000000 | JPY |
| Gross profit | Prior1InterimDuration | 15907000000 | JPY |
| Gross profit | InterimDuration | 16985000000 | JPY |
| Selling general and administrative expenses | Prior1InterimDuration | 12561000000 | JPY |
| Selling general and administrative expenses | InterimDuration | 14335000000 | JPY |
| Operating income | Prior1InterimDuration | 3345000000 | JPY |
| Operating income | InterimDuration | 2649000000 | JPY |
| Interest income noi | Prior1InterimDuration | 1000000 | JPY |
| Interest income noi | InterimDuration | 21000000 | JPY |
| Dividends income noi | Prior1InterimDuration | 148000000 | JPY |
| Dividends income noi | InterimDuration | 176000000 | JPY |
| Other noi | Prior1InterimDuration | 55000000 | JPY |
| Other noi | InterimDuration | 173000000 | JPY |
| Non operating income | Prior1InterimDuration | 204000000 | JPY |
| Non operating income | InterimDuration | 371000000 | JPY |
| Interest expenses noe | Prior1InterimDuration | 22000000 | JPY |
| Interest expenses noe | InterimDuration | 109000000 | JPY |
| Foreign exchange losses noe | Prior1InterimDuration | － | JPY |
| Foreign exchange losses noe | InterimDuration | 92000000 | JPY |
| Loss on disposal of noncurrent assets noe | Prior1InterimDuration | 101000000 | JPY |
| Loss on disposal of noncurrent assets noe | InterimDuration | 72000000 | JPY |
| Other noe | Prior1InterimDuration | 113000000 | JPY |
Every row of the EDINET CSV. Item names are the XBRL element names; filed text is kept in its original Japanese. Filed text is available on Plus and Pro.
Data checks · 14 of 14 passed
| balance sheet identity | pass rounding |
| balance sheet identity | pass rounding |
| dei present | pass |
| period resolution | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net income attributable to parent | pass |
| statement vs summary · net income attributable to parent | pass |
| statement vs summary · operating cash flow | pass |
| statement vs summary · operating cash flow | pass |
| statement vs summary · revenue | pass |
| statement vs summary · revenue | pass |
| statement vs summary · total assets | pass |
| statement vs summary · total assets | pass |